Similar to these findings, in a small trial CB Tregs were given to two COVID-19 patients with ARDS, resulting in a significant reduction of inflammatory markers including IL-6, IL-12, TNF-α, IFN-γ and MCP-1, without adverse reactions [173]. The gene discussed is IL6; the disease is COVID-19.